QPPV.COM KNOWLEDGE ASSESSMENT

Abatacept: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Abatacept: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should the small COPD subgroup finding in the US label be used when reviewing a COPD exacerbation case?
Question 2 of 10 A patient has an acute reaction during an abatacept infusion. Which information is most useful for clinical and pharmacovigilance characterisation?
Question 3 of 10 Why should an abatacept safety analysis distinguish intravenous from subcutaneous exposure?
Question 4 of 10 What is the most appropriate interpretation of the 1991 CTLA4–Ig experiment in relation to marketed abatacept?
Question 5 of 10 A reviewer sees CMV and EBV precautions in the US transplant label and not in the assessed EU SC rheumatology product information. What is the best interpretation?
Question 6 of 10 Which statement best reflects the distinction between remission during treatment and drug-free remission in AVERT?
Question 7 of 10 A patient with active rheumatoid arthritis has inadequate disease control after a TNF inhibitor. Which conclusion is best supported by the ATTAIN evidence described in the article?
Question 8 of 10 A spontaneous-report database shows a higher proportion of a particular event for abatacept than for other medicines. What can this finding support?
Question 9 of 10 A patient has an infection after abatacept administration. Which statement best describes the relationship between event occurrence and medication error?
Question 10 of 10 What is the correct interpretation of AMPLE's one-year ACR20 result for subcutaneous abatacept versus adalimumab, both with methotrexate?

Select an answer to continue.

QPPV.com